A neuroscience company that focuses on the development of a small molecule drug for Alzheimer’s disease (AD). The compound is a potential first-in-class, oral inhibitor of selected ion channels that are thought to be pathologically and epidemiologically upstream of cognitive deficits and behavioral and psychological symptoms of dementia (BPSD).
Investors 1
| Date | Name | Website |
| - | Fast Track... | us.fasttra... |
Mentions in press and media 1
| Date | Title | Description |
| 03.03.2024 | Neusignal Therapeutics Co., Ltd. Neusignal Therapeutics raised SeedRound approximately 1.33 billion yen from a total of 5 companies including Fast Track Initiative Co., Ltd. and Keio Innovation Initia... | Neusignal Therapeutics Co., Ltd. Neusignal Therapeutics raises SeedRound approximately 1.33 billion yen from 5 companies including Fast Track Initiative Co., Ltd. and Keio Innovation Initiative Co., Ltd. and AMED subsidy Accelerating clinic... |